Developing a new treatment to protect against radiation damage
DEVELOPMENT OF ANTICERAMIDE TREATMENT AS A NOVEL MEDICAL COUNTERMEASURE FOR ACUTE EFFECTS OF RADIATION EXPOSURE
This study is testing a new treatment called CX-01 that aims to protect blood vessels from damage caused by radiation, which could help people who have been exposed to harmful radiation avoid serious health issues.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ceramedix Holding, LLC NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11118646 on NIH RePORTER |
What this research studies
This research focuses on creating a new medical countermeasure called CX-01, which aims to prevent damage caused by radiation exposure, particularly to the microvascular system. By targeting the early stages of radiation injury, CX-01 seeks to inhibit cell death in the blood vessels, which can lead to severe gastrointestinal complications. The research involves extensive animal studies to model the effects of radiation and test the effectiveness of this novel treatment. If successful, this could provide a critical solution for individuals exposed to harmful radiation.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals at risk of radiation exposure, such as those involved in nuclear accidents or certain medical treatments.
Not a fit: Patients who have not been exposed to radiation or those with pre-existing severe gastrointestinal conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a groundbreaking treatment option for patients suffering from acute radiation syndrome.
How similar studies have performed: While there is ongoing research in radiation countermeasures, the specific approach of CX-01 is novel and has not been previously tested in this context.
Where this research is happening
New York, United States
- Ceramedix Holding, LLC — New York, United States (Active)
Researchers
- Principal investigator: Dimmler Iii, Charles — Ceramedix Holding, LLC
- Study coordinator: Dimmler Iii, Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.